Table 3.

Dose modification for mirvetuximab for ocular adverse events (AE). Modified from https://www.elaherehcp.com/dosing#modifications. Starting dose 6 mg/kg adjusted body weight (ABW). 1st dose reduction 5 mg/kg ABW, 2nd dose reduction 4 mg/kg ABW.

Severity	Dose Modification
Keratitis Nonconfluent superficial Confluent superficial, cornea epithelial defect or 3-line or more loss in corrected VA1 Corneal ulcer, stromal opacity, corrected VA 20/200 or worse Corneal perforation	Monitor Hold dose until improved or resolved, maintain same dose or consider dose reduce 1 level Hold dose until improved or resolved, dose reduce 1 level Permanently discontinue
Uveitis Grade 1: rare cell in anterior chamber 2: 1–2 + cell or flare in anterior chamber 3: 3 + cell or flare in anterior chamber 4: Hypopyon	Monitor Hold dose until Grade ≤ 1, then resume same dose Hold dose until Grade ≤ 1, dose reduce 1 level Permanently discontinue

¹VA visual acuity.